ABT · 8-K · 20260716PR048377

Acquisition / Partnership / Divestiture

ABBOTT LABORATORIES · 2026-07-16 · Importance 65 · Surprise 60 · In source text

Abbott completed its acquisition of Exact Sciences on March 23, 2026, and presents Exact Sciences sales within Cancer Diagnostics. Exact Sciences contributed $811 million of reported second-quarter sales and $706 million of reported first-half sales, with $786 million and $681 million, respectively, from the U.S. Abbott recorded $532 million of first-half pre-tax acquisition-related expenses, including accelerated stock-based compensation, integration costs, and inventory step-up amortization. Cancer Diagnostics generated $919 million of second-quarter sales and comparable growth of 13.3%, driven by mid-teens Cologuard growth and contributions from precision oncology and international operations.

Key facts

• On March 23, 2026 Abbott acquired Exact Sciences and completed the acquisition on that date. source
• The acquisition adjustment for Exact Sciences included historical sales of $811 million in 2Q25 for revenue reconciliation. source
• In 2Q26 specified items, acquisition-related gross-margin impact was $32 million and restructuring and cost reduction initiatives gross-margin impact was $4 million. source
• Abbott stated the final payment under the multi-year agreement with a competitor was recognized in the first quarter of 2026 and impacted Structural Heart compensation payments of $89 million in 2025. source

Impact estimates